VBL Therapeutics Announces That S-4 Registration Statement For Proposed Merger With Notable Labs Is Declared Effective By SEC
Merger with Notable expected to close in mid-October, subject to shareholder approval
Special shareholder meeting scheduled for October 12, 2023
MODI'IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. ("Notable") has been declared effective by the U.S. Securities and Exchange Commission ("SEC").
The definitive merger agreement between VBL and Notable was announced on February 23, 2023 and is expected to close in mid-October 2023, subject to customary closing conditions, including approval of the merger by VBL's shareholders. The registration statement contains a proxy statement / prospectus / information statement in connection with the merger. A copy of the registration statement can be found here.
"Having our registration statement on Form S-4 declared effective by the SEC is an important step towards the closing of our previously announced merger with Notable," said Prof. Dror Harats, M.D., Chief Executive Officer of VBL. "We believe this merger represents the best path forward for the shareholders of both companies and for patients. The combined organization is expected to be listed on Nasdaq, and plans to apply Notable's Predictive Precision Medicines Platform to develop a pipeline of clinical-stage precision medicines with the goal of transforming the standard of care in oncology."